The study was designed to compare the response to almotriptan in migraine patients who
take medication early in the course of the attack with that when medication is taken after pain …

An important issue in the management of migraine is the advice given to patients as to when
to take their treatment in the course of the attack. While it seems common sense almost to …

Objective.—To determine whether treatment of migraine with almotriptan, when pain
intensity is mild, improves 1‐and 2‐hour pain‐free and sustained pain‐free rates compared …

Background.—Results from open‐label trials with almotriptan and sumatriptan have shown
higher response rates when treatment was initiated early after acute migraine onset …

Objective.—To evaluate prospectively the efficacy and safety of almotriptan 12.5 mg as
compared to placebo when administered within 1 hour of headache pain onset for the acute …

Background.—Migraine sufferers typically have been instructed to delay triptan therapy until
headache intensity is at least moderate. Recent data suggest that earlier use of triptans may …

In this double-blind study, the efficacy and tolerability of a single dose of almotriptan (6.25 or
12.5 mg) was compared with placebo in the treatment of three consecutive migraine attacks …

Almotriptan is a novel and specific serotonin 5-HT1B/1D agonist for the acute treatment of
migraine. This randomized, single-dose, double-blind, multicentre, study assessed the …

In this randomized, double‐blind, crossover clinical trial, adult patients treated two migraine
attacks: one with almotriptan 12.5 mg and the other with ergotamine 2 mg plus caffeine 200 …

Background: Almotriptan is a highly specific 5-HT 1B/1D receptor agonist, which acts
selectively on blood vessels of the brain. Short-term studies have demonstrated that …